Price T Rowe Associates Inc Alkermes Plc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 8,326,256 shares of ALKS stock, worth $202 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
8,326,256
Previous 1,595,585
421.83%
Holding current value
$202 Million
Previous $44.3 Million
409.22%
% of portfolio
0.03%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding ALKS
# of Institutions
357Shares Held
180MCall Options Held
522KPut Options Held
463K-
Black Rock Inc. New York, NY29.2MShares$707 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA20.2MShares$489 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.9MShares$361 Million0.07% of portfolio
-
State Street Corp Boston, MA9MShares$218 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.05MShares$147 Million2.63% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $3.98B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...